ClassID:

94184

C07D211/86 - CPC Classification

Classification description:

Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms Oxygen atoms

Sub-classes:
Recent Application in this class:
#1
20260116927
2026-04-30

Synthesis of GLP-1R/GIPR Agonists and Precursors Thereof

#2
20250250226
2025-08-07

IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF

#3
20250214930
2025-07-03

TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA

#4
20250163033
2025-05-22

METHODS OF TREATING CANCER

#5
20240398959
2024-12-05

C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION

#6
20240300893
2024-09-12

SMALL MOLECULE COMPOUNDS TARGETING SRSF6 PROTEIN AND THEIR PREPARATION METHODS AND APPLICATIONS

#7
20240254079
2024-08-01

Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha

#8
20240059654
2024-02-22

INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY

#9
20230183168
2023-06-15

IONIZABLE LIPIDS AND COMPOSITIONS AND USES THEREOF

#10
20230045142
2023-02-09

SMALL MOLECULE RPN13 INHIBITORS WITH ANTITUMOR PROPERTIES

#11
20230021476
2023-01-26

Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha

#12
20220315566
2022-10-06

Methods of treating cancer

#13
20220313826
2022-10-06

C-carbon linked glutarimide degronimers for target protein degradation

#14
20220242820
2022-08-04

Ionizable compounds and compositions and uses thereof

#15
20220213080
2022-07-07

Piperlongumine-based compound and immuno regulator comprising the same

#16
20220185778
2022-06-16

PROLYL HYDROXYLASE INHIBITORS

#17
20220000856
2022-01-06

1',3'-Disubstituted-4-Phenyl-3,4,5,6-Tetrahydro-2H,1'H-[1,4']Bipyridinyl-2'-Ones

#18
20210371384
2021-12-02

Inhibitors of the WNT/beta-catenin pathway

#19
20210317079
2021-10-14

Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2α

#20
20210198235
2021-07-01

Derivatives of piperlongumine and uses thereof

#21
20210161869
2021-06-03

ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS

#22
20210122714
2021-04-29

Crystal forms of oxypyridine amide derivative and preparation method therefor

#23
20200281905
2020-09-10

Aryl dihydropyridinones and piperidinone MGAT2 inhibitors

#24
20200262823
2020-08-20

METHODS OF TREATING CANCER

#25
20200048201
2020-02-13

Methods for enantioselective allylic alkylation of esters, lactones, and lactams with unactivated allylic alcohols

#26
20200038391
2020-02-06

1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones

#27
20190382378
2019-12-19

Substituted glycine derived FXIA inhibitors

#28
20190321343
2019-10-24

Anti-fibrotic pyridinones

#29
20190314346
2019-10-17

Aryl dihydropyridinones and piperidinone MGAT2 inhibitors

#30
20190135754
2019-05-09

Methods for enantioselective allylic alkylation of esters, lactones, and lactams with unactivated allylic alcohols

#31
20190127318
2019-05-02

Ionizable compounds and compositions and uses thereof

#32
20190100514
2019-04-04

METHODS OF TREATING CANCER

#33
20190076542
2019-03-14

C3-carbon linked glutarimide degronimers for target protein degradation

#34
20190055198
2019-02-21

Prolyl hydroxylase inhibitors

#35
20190008866
2019-01-10

BROMODOMAIN INHIBITORS

#36
20180370966
2018-12-27

METHODS OF TREATMENT USING PYRIDINONYL PDK1 INHIBITORS

#37
20180362528
2018-12-20

Process for the preparation of apixaban and intermediates thereof

#38
20180353492
2018-12-13

Non-aromatic heterocyclic derivative having MGAT2 inhibitory activity

#39
20180279614
2018-10-04

Pyridone compounds and agricultural and horticultural fungicides containing said compounds as active ingredient

#40
20180265444
2018-09-20

Small molecule stimulators of steroid receptor coactivator proteins and their use in the treatment of cancer

#41
20180244693
2018-08-30

Process for the preparation of dolutegravir

#42
20180222889
2018-08-09

Substituted glycine derived FXIA inhibitors

#43
20180207144
2018-07-26

Enhancer of Zeste Homolog 2 inhibitors

#44
20180133198
2018-05-17

Aryl dihydropyridinones and piperidinone MGAT2 inhibitors

#45
20180118661
2018-05-03

Compounds and methods for the treatment of neurodegenerative diseases

#46
20180099963
2018-04-12

Process for the preparation of Apixaban and intermediates thereof

#47
20180064692
2018-03-08

Anti-fibrotic pyridinones

#48
20180044288
2018-02-15

Kinase inhibitors

#49
20170362232
2017-12-21

Process for the preparation of Apixaban and intermediates thereof

#50
20170305890
2017-10-26

METHODS OF TREATING CANCER

#51
20170305889
2017-10-26

METHODS OF TREATING CANCER

#52
20170298019
2017-10-19

PROLYL HYDROXYLASE INHIBITORS

#53
20170216263
2017-08-03

Aryl dihydropyridinones and piperidinone MGAT2 inhibitors

#54
20170088518
2017-03-30

Fluorinated derivatives of 3-hydroxypyridin-4-ones

#55
20170015663
2017-01-19

Process for the preparation of apixaban and intermediates thereof

#56
20170001990
2017-01-05

PIPERIDINE-DIONE DERIVATIVES

#57
20160376232
2016-12-29

Kinase inhibitors

#58
20160376229
2016-12-29

Ionizable compounds and compositions and uses thereof

#59
20160331749
2016-11-17

Bromodomain inhibitors

#60
20160263090
2016-09-15

Anti-fibrotic pyridinones

#61
20160067162
2016-03-10

PHOTOPROTECTIVE COMPOUNDS, COMPOSITIONS INCLUDING SAME AND USES THEREOF

#62
20160031816
2016-02-04

Aryl dihydropyridinones and piperidinone MGAT2 inhibitors

#63
20150353541
2015-12-10

Intermediate and polymorphs of 1-(4-methoxypheny1)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetra hydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide and process thereof

#64
20150335667
2015-11-26

Substituted (3S,11AR)-N-[(2,4-difluorophenyl)methyl]-6-oxy-3-methyl-5,7-dioxo-2,3,5,7,11,11A-hexahydro[1,3]oxazolo[3,2-A]pyrido[1,2-D]pyrazine-8-carboxamides as HIV agents

#65
20150335626
2015-11-26

Fluorinated derivatives of 3-hydroxypyridin-4-ones

#66
20150299124
2015-10-22

SYNTHESIS OF UV ABSORBING COMPOUNDS

#67
20150218098
2015-08-06

Prolyl hydroxylase inhibitors

#68
20150183784
2015-07-02

Bromodomain inhibitors

#69
20150175559
2015-06-25

CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS

#70
20150158873
2015-06-11

Bromodomain inhibitors

#71
20150157617
2015-06-11

Methods for increasing the stabilization of hypoxia inducible factor-α

#72
20150157616
2015-06-11

Dihydropyridin-2(1H)-one compounds as -nitrosoglutathione reductase inhibitors and neurokinin-3 receptor antagonists

#73
20150126522
2015-05-07

Enhancer of zeste homolog 2 inhibitors

#74
20150119412
2015-04-30

Heterocyclic compound

#75
20150025242
2015-01-22

Apixaban preparation process

#76
20150018351
2015-01-15

Methods of treatment using pyridinonyl PDK1 inhibitors

#77
20140357670
2014-12-04

Dihydropyridinone MGAT2 inhibitors

#78
20140343031
2014-11-20

N-link hydroxamic acid derivatives useful as antibacterial agents

#79
20140296271
2014-10-02

Kinase inhibitor

#80
20140296208
2014-10-02

Kinase inhibitors

#81
20140256961
2014-09-11

2-(2-hydroxy-2-phenylethyl)-3-[(phenylmethyl)oxy]-4H-pyran-4-one of the formula P-3 and/or 2-[(E)-2-phenylethenyl]-3-[(phenylmethyl)oxy]-4H-Pyran-4-one of the formula P-4

#82
20140256679
2014-09-11

Substituted (3S, 11aR)-N-[(2,4-difluorophenyl)methyl]-6-oxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamides of formula (I) useful as HIV agents

#83
20140128393
2014-05-08

Methods of treating cancer

#84
20140128363
2014-05-08

N-link hydroxamic acid derivatives useful as antibacterial agents

#85
20140107110
2014-04-17

Anti-fibrotic pyridinones

#86
20140058107
2014-02-27

Apixaban preparation process

#87
20140039207
2014-02-06

4-oxo-3-[(phenylmethyl)oxy]-4H-pyran-2-carboxylic acid

#88
20140031555
2014-01-30

1-(2,3-dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylic acid of the formula P-6 and/or methyl 1-(2,3-dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylate of the formula P-7

#89
20140024639
2014-01-23

Compounds, compositions, and methods for cancer therapy

#90
20130197019
2013-08-01

1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro--[1,4′]bipyridinyl-2′-ones

#91
20130196992
2013-08-01

1',3'-DISUBSTITUTED-4-PHENY-3,4,5,6-TETRAHYDRO-2H,1'H-[1,4']BIPYRIDINYL-2'-ONES

#92
20130096161
2013-04-18

Dihydropyridin-2(1H)-one compound as S-nirtosoglutathione reductase inhibitors and neurokinin-3 receptor antagonists

#93
20130053565
2013-02-28

SUBSTITUTED 3-PIPERIDONE COMPOUNDS

#94
20130005744
2013-01-03

Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders

#95
20120270882
2012-10-25

Fluorinated derivates of 3-hydroxypyridin-4-ones

#96
20120258948
2012-10-11

N-linked hydroxamic acid derivatives useful as antibacterial agents

#97
20120220596
2012-08-30

Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings

#98
20120157455
2012-06-21

Compounds And Compositions For Treating Cancer

#99
20120059004
2012-03-08

Compounds and compositions for treating cancer

#100
20110269715
2011-11-03

ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE

#101
20110251388
2011-10-13

1-heterodiene derivative and harmful organism control agent

#102
20110245210
2011-10-06

Thalidomide analogs

#103
20110183940
2011-07-28

Methyl 3-(benzyloxy)-1-(2,2-dihydroxyethyl)-4-oxo-1,4-dihydropyridine-2-carboxylate and processes for the preparation thereof

#104
20110118300
2011-05-19

Glucose metabolism modulating compounds

#105
20110112055
2011-05-12

Compositions and methods for treating colitis

#106
20110111058
2011-05-12

Methods for increasing the stabilization of hypoxia inducible factor-1 alpha

#107
20110110961
2011-05-12

Prolyl hydroxylase inhibitors

#108
20110053938
2011-03-03

Compounds and compositions for treating cancer

#109
20100286207
2010-11-11

Novel 2-Oxo-Heterocyclic Compounds And The Pharmaceutical Compositions Comprising The Same

#110
20100240688
2010-09-23

1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-[1,4′] bipyridinyl-2′-ones

#111
20100160389
2010-06-24

Dihydropyridone amidesas P2Xmodulators

#112
20100160388
2010-06-24

Dihydropyridone ureas as P2Xmodulators

#113
20100160387
2010-06-24

Dihydropyridone amides as P2X7 modulators

#114
20100144730
2010-06-10

Pyridinonyl PDK1 inhibitors

#115
20100087442
2010-04-08

Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient

#116
20100010027
2010-01-14

Abnormal cannabidiols as agents for lowering intraocular pressure

#117
20100004237
2010-01-07

2-Amino-7,8-dihydro-6H-pyrido[4,3-D]pyrimidin-5-ones

#118
20090312373
2009-12-17

METHODS FOR THE TREATMENT OF CANCER USING PIPERLONGUMINE AND PIPERLONGUMINE ANALOGS

#119
20090281109
2009-11-12

Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings

#120
20090124668
2009-05-14

Cyclic derivatives as modulators of chemokine receptor activity

#121
20090062279
2009-03-05

Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents

#122
20080081825
2008-04-03

Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof

#123
20070265165
2007-11-15

NOVEL HERBICIDES

#124
20070249602
2007-10-25

Abnormal Cannabidiols as agents for lowering intraocular pressure

#125
20070249596
2007-10-25

Abnormal cannabidiols as agents for lowering intraocular pressure

#126
20070167486
2007-07-19

2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same

#127
20070149513
2007-06-28

Vanilloid receptor ligands and their use in treatments

#128
20070123546
2007-05-31

2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones

#129
20070032526
2007-02-08

Cyclic derivatives as modulators of chemokine receptor activity

#130
20070027186
2007-02-01

SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO[3,4-C]PYRID-2-ONES

#131
20060211728
2006-09-21

Thalidomide analogs

#132
20060177621
2006-08-10

O-coordinated metal chelates and their use in optical recording media having high storage capacity

#133
20060173043
2006-08-03

2-oxo-heterocyclic compounds and pharmaceutical compositions

#134
20060111303
2006-05-25

Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient

#135
20060084688
2006-04-20

Aromatic sulfone hydroxamic acid metalloprotease inhibitor

#136
20060019996
2006-01-26

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

#137
20060019995
2006-01-26

2,3-dihydro-4(1H)-pyridone derivatives , method for production thereof and pharmaceutical composition comprising the same

#138
20060014836
2006-01-19

Substituted aryl thioureas and related compounds; inhibitors of viral replication

#139
20050261342
2005-11-24

Metabolites of (+)-(2S,3S)-3(2-methoxy-5- trifluoromethoxybenzylamino)-2-phenyl-piperidine

#140
20050245566
2005-11-03

Synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones

#141
20050187110
2005-08-25

Herbicides

#142
20050164883
2005-07-28

Herbicides

#143
20050085509
2005-04-21

Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient

#144
20050054627
2005-03-10

Cyclic derivatives as modulators of chemokine receptor activity

#145
20050043538
2005-02-24

Peptide beta-strand mimics based on 1,2-dihydro-3(6H)-pyridinone

#146
20050038072
2005-02-17

Nitrogeneous cyclic ketone derivative, process for producing the same, and use